Open-label, Single-arm, Phase IV, Multicenter Trial to Explore the Immunogenicity of the Liquid Formulation of Saizen in Subjects With Adult Growth Hormone Deficiency (AGHD)

Trial Profile

Open-label, Single-arm, Phase IV, Multicenter Trial to Explore the Immunogenicity of the Liquid Formulation of Saizen in Subjects With Adult Growth Hormone Deficiency (AGHD)

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2018

At a glance

  • Drugs Somatrogon (Primary)
  • Indications Somatotropin deficiency
  • Focus Pharmacodynamics
  • Sponsors Merck KGaA
  • Most Recent Events

    • 27 Feb 2018 Results published in the Journal of Endocrinological Investigation
    • 10 Jun 2017 Biomarkers information updated
    • 04 Apr 2017 Results presented at The 99th Annual Meeting of the Endocrine Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top